Introduction: Lung cancer, especially non-small cell lung cancer (NSCLC), is a major public health concern and the leading cause of cancer-related mortality worldwide. Dysregulated long non-coding RNAs (lncRNAs) can influence gene signaling networks, contributing to tumorigenesis. Recent research in LC has increasingly focused on lncRNAs as promising candidates for biomarker identification. Objectives: to identify potential lncRNAs as biomarkers and pathways involved in the cancerization field of NSCLC. Methods: Samples from lung cancer patients treated at reference hospital were divided into two groups: Tumoral (n=18) and adjacent (n=9), with sample collection approved by Ethics and Research Committee (CAAE_41667021.4.3001.0017). Total RNA was extracted using the Biospin Total RNA Extraction II kit (BioFlux), and library preparation for sequencing was performed with the TruSeq Stranded Total with Ribozero (Illumina) kit. The NGS platform used was the Nextseq 500/550 (paired-end, Illumina). Read quality assessment was conducted using the Fastp software (Minimum QV > 15). Transcript reads were aligned using the Salmon program, utilizing the "gencode.43.complete" index for human coding and non-coding transcript information. Data manipulation, statistical analysis, differential expression (DE), and generation of graphs were performed using the RStudio software with packages including tximport, DESeq2, ggplot2, and ComplexHeatmap. To select the best biomarkers, pROC (AUC > 0.9) was used. Functional enrichment of lncRNAs was generated through the ClusterProfiler package (GSEA), with "Hallmarks" category. Results: 1,147 DE lncRNAs were identified, of which 447 were down-regulated and 700 were up-regulated. PCoA analysis showed that the groups have significantly different expression profiles (PERMANOVA; p-value = 0.001). Of the total DE transcripts, the ROC curve classified 58 DE transcripts, which formed three clusters in a heat map and were used in subsequent analyses. Cluster 1: containing 30 lncRNAs (such as SFTA1P, FENDRR) down-regulated in the tumor and up-regulated in the adjacent tissue, being involved in gene regulation processes, response to oxidative stress and inflammation; Cluster 2 and 3: having 12 (such as CASC19, DDX11-AS1) and 16 transcripts (such as ZFPM2-AS1), respectively, in which both are hyperregulated in the tumor and low, in the adjacent region, whose functionalities are linked to cell proliferation/metastasis promotion (cluster 1) and modulation of miRNAs, metastasis, epigenetic control, and modulation of inflammation (cluster 2). Furthermore, among the most expressive biological pathways in the transcriptomic data are: TNFA/NFKB, comprising the majority of non-coding transcripts; inflammatory response; IL6/JAK-STAT3 signaling; IFN Gamma; EMT process; KRAS signaling. Conclusion: The results of this study reveal the central role of lncRNAs in the regulation of critical pathways associated with inflammation, cell proliferation, epigenetic control and miRNA modulation in tumor and adjacent tissues, evidencing their active participation in the cancerization process. The functional distinction between the identified clusters suggests that changes in the expression profile of lncRNAs are not restricted to the tumor, but also affect adjacent regions, contributing to a microenvironment conducive to tumor progression. These findings expand the understanding of the molecular mechanisms involved in the initiation and progression of lung cancer, positioning lncRNAs as potential biomarkers and promising therapeutic targets in oncology.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
